GlobeNewswire by notified

Clariant reports markedly stronger sales growth and EBITDA expansion in Q1 2022



  • First quarter 2022 sales from continuing operations increased by 30 % in local currency and 26 % in Swiss francs to CHF 1.262 billionpricing contributed 16 % to the strong top-line growth
  • Continuing operations EBITDA was up 27% to CHF 220 million
  • EBITDA margin increased to 17.4 % from 17.3 % in the first quarter of 2021
  • First quarter performance underlines the ability to achieve mid-term targets
  • Outlook 2022: Strong local currency growth for the Group with the aim to improve
    year-on-year Group EBITDA margin level in a challenging geopolitical environment

“I’m proud to announce that Clariant had a strong start to 2022 despite the turbulent environment. In the first quarter, we successfully generated compelling revenue growth and clearly increased absolute EBITDA. The Group’s higher-value specialty portfolio once again enabled us to successfully manage continued variable cost inflation arising from raw materials, energy, and logistics services,” said Conrad Keijzer, CEO of Clariant. “Although the short-term macroeconomic uncertainty remains high, we are well on track to deliver on our mid-term targets.”

Key Financial Data

Continuing operations First Quarter
in CHF million 20222021% CHF% LC
Sales 1 262 1 002 26 30
EBITDA 220 1731 27
- margin 17.4 % 17.3 %
EBITDA before exceptional items238178134
- margin18.9 %17.8 %

1 restated

First Quarter 2022 Verystrong sales growth

MUTTENZ, JUNE 15, 2022

Clariant, a focused, sustainable, and innovative specialty chemicals company, today announced first quarter 2022 continuing operations sales of CHF 1.262 billion, compared to CHF 1.002 billion in the first quarter of 2021. This corresponds to a particularly strong increase of 30 % in local currency and 26 % in Swiss francs. The positive pricing impact of 16 % in part addressed continued cost inflation and also slightly outpaced the volume growth of 14 %. Care Chemicals and Natural Resources grew sales at an accelerated pace, which more than compensated for the expected slightly weaker development in Catalysis.

All geographic regions contributed meaningfully to the sales expansion in the first quarter of 2022, reflecting both continued strong demand as well as supply chain shortages. In Europe, the high 27 % local currency growth was underpinned by strong expansion in Care Chemicals as well as Natural Resources. Sales in Asia-Pacific rose by 31 %, underpinned by expansion in all Business Areas and clearly driven by 34 % higher sales in China. The Americas reported compelling growth as North American sales increased by a resounding 37 %, followed closely by Latin America at 31 %. In the Middle East & Africa, sales rose by 26 %.

In the first quarter of 2022, Care Chemicals increased sales by 44 % in local currency. This progress was supported by double-digit expansion in both Consumer Care and Industrial Applications, in particular Personal Care, Crop Solutions, Aviation, and Coatings. The consolidation of the acquired majority share in Clariant IGL Specialty Chemicals (CISC) and the acquisition of the remaining shares in Beraca further supported this positive development with an addition of 4 % local currency volume growth for the Group. Catalysis sales decreased by a slight 1 % in local currency, despite significantly higher Specialty Catalysts sales, which could not entirely counterbalance the weakness in parts of Petrochemicals and Syngas. Natural Resources sales increased by a resounding 31 % in local currency with growth attributable to all three Business Units, especially Additives.

The continuing operations EBITDA increased to CHF 220 million with a corresponding margin of 17.4 %, slightly exceeding the 17.3 % reported in the first quarter of the previous year. The increase was underpinned by operating leverage from higher sales, cost savings (CHF 4 million savings from efficiency programs), and pricing measures, which largely offset raw material price increases, supply chain constraints, and higher energy and logistics cost. The absolute EBITDA increased by a notable 27 %.

Discontinued Operations

Clariant’s Pigments business was divested to a consortium comprising Heubach Group and SK Capital Partners on 3 January 2022, which resulted in a provisional pretax disposal gain of CHF 168 million and an EBITDA of CHF 160 million for discontinued operations. Total Group (continuing operations and discontinued operations) EBITDA was CHF 380 million in the first quarter of 2022.

Outlook – Full Year 2022

Clariant aims to grow above the market to achieve higher profitability through sustainability and innovation. The Group concluded the final step in its significant portfolio transformation in January of 2022. Clariant is now a truly specialty chemicals company and confirms its 2025 ambition to deliver profitable growth (4 – 6 % CAGR), a Group EBITDA margin between 19 – 21 %, and a free cash flow conversion of around 40 %.

In the second quarter of 2022, Clariant expects to generate continued strong sales growth in local currency versus the prior year, underpinned by expansion in all Business Areas despite a normalizing growth environment. Sequential sales are expected to decline moderately as a result of seasonal impacts (aviation, refinery) and demand normalization in Care Chemicals and Natural Resources. Clariant expects to improve on its restated year-on-year margin levels in the second quarter of 2022. Sequentially, the Group expects to be broadly in line with its first quarter 2022 margin level, especially via operating leverage from growth, continuing pricing actions, and cost discipline to counter continued inflation in raw materials, logistics, labor, and energy cost.

For the full year 2022, Clariant expects strong growth in local currency for the Group, driven by a particularly strong first half of 2022. The current high level of uncertainty resulting from the geopolitical conflicts, suspension of business with Russia, and the resurgence of COVID-19 in China are expected to continue to impact global economic growth and consumer demand in the second half of the year. Clariant expects the high inflationary environment with regard to raw material, energy, and logistics cost as well as supply chain challenges to persist in the second half of 2022. Clariant aims to improve its year-on-year Group EBITDA margin levels via solid revenue growth driven by pricing and continued cost discipline, despite the increasingly challenging economic environment.

Q1 2022 Media Release EN


Jochen Dubiel
Phone +41 61 469 63 63

Anne Maier
Phone +41 61 469 63 63

Ellese Caruana
Phone +41 61 469 63 63


Andreas Schwarzwälder
Phone +41 61 469 63 73

Maria Ivek
Phone +41 61 469 63 73

Alexander Kamb
Phone +41 61 469 63 73
Follow us on Twitter, Facebook, LinkedIn, Instagram.

This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

Clariant is a focused, sustainable, and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2021, Clariant totaled a staff number of 11 537 and recorded sales of CHF 4.372 in the fiscal year for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is led by the overarching purpose of ‘Greater chemistry – between people and planet,’ and reflects the importance of connecting customer focus, innovation, sustainability, and people.
To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy30.6.2022 10:00:00 CEST | Press release

First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal squamous cell carcinoma1 Statistically significant survival benefit with tislelizumab plus chemotherapy was observed regardless of PD-L1 status and consistent across all patient subgroups1 Novartis to discuss results of multi-regional RATIONALE 306 study, the seventh positive Phase III trial readout for tislelizumab, with regulatory health authorities Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 m

Huhtamaki publishes 2022 Half-yearly Report on July 21, 202230.6.2022 09:00:00 CEST | Press release

HUHTAMÄKI OYJ PRESS RELEASE 30.6.2022 AT 10:00 Huhtamaki publishes 2022 Half-yearly Reporton July21, 2022 Huhtamäki Oyj will publish its 2022 Half-yearly Report on Thursday, July 21, 2022, approximately at 8.30 am Finnish time (EEST). The release and related results presentation material will be available after publishing at Teleconference Huhtamaki will arrange a combined audiocast and teleconference on the same day at 9.30 am Finnish time, where the company’s management will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland Toll: +358981710310 Sweden Toll: +46 856642651 United Kingdom Toll: +44 3333000804 United States Toll: +1 6319131422 Confirmation code for the call is 23337170# An on-demand replay of the audiocast w

Fingerprints announces design win for its optical under-display solution with major Asian smartphone OEM30.6.2022 08:00:00 CEST | Press release

Fingerprint Cards AB (Fingerprints™) today announced that it has secured a design win* for its optical under-display solution, FPC 1632, with a major Asian smartphone OEM, following successful qualification tests earlier this year. We expect to commence shipments during the fourth quarter of 2022. “Since many years, Fingerprints is a well-established world leader in capacitive fingerprint sensors. The design win we are announcing today marks our entry into a new market segment: optical under-display fingerprint sensors. This will open up attractive new growth opportunities for us going forward, and our goal is to capture a significant share of this market,” says Ted Hansson, President Mobile, PC & Access China at Fingerprints. For more information about Fingerprints’ mobile device solutions, visit the website. * Fingerprints’ definition of Design Win (DW): The decision by a device vendor (OEM or ODM) to start development of one or several commercial product(s) incorporating Fingerprint

Inaugural Yara Clean Ammonia Capital Markets Day30.6.2022 08:00:00 CEST | Press release

Oslo, 30 June 2022: Today, Yara International ASA (“Yara”) will host a Capital Markets Day (“CMD”) for Yara Clean Ammonia (“YCA” or the “Company”). During the event, members of YCA’s management team will present key features of the Company, including its strategy and growth ambitions, as well as financial parameters and targets for the future. In May 2022, Yara announced that it is evaluating a potential initial public offering (“IPO”) of YCA on the Oslo Stock Exchange. “While the decision to list YCA will be made in due course, Yara is now excited to host an inaugural CMD for YCA to showcase their exciting story,” said Svein Tore Holsether, CEO and President of Yara. “YCA combines a leading midstream business with exceptional growth prospects and a value creating project portfolio.” Key highlights: Clean ammonia represents a massive opportunity that is projected to drive exponential, long-term market growth [1].YCA comprises existing cash flows from a market leading position [2] in a